BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 36,209 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the completion of the sale, the chief executive officer owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, October 8th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $92.31, for a total value of $2,492,370.00.
• On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The stock was sold at an average price of $96.81, for a total value of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.

BioNTech Stock Up 5.3%

NASDAQ:BNTX opened at $96.96 on Friday. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The stock has a market cap of $24.52 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25. The stock has a 50-day moving average price of $99.17 and a two-hundred day moving average price of $95.17.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The business had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period in the prior year, the business earned ($1.60) EPS. The company’s revenue for the quarter was down 59.5% compared to the same quarter last year. As a group, equities analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Biotech-sector momentum offered a modest tailwind after Moderna’s inclusion in the Nasdaq-100 triggered a sharp move in its shares, while BioNTech also traded higher alongside other major vaccine companies. Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
• Neutral Sentiment: Argus initiated coverage with a Hold rating, adding a cautious view but no immediate change to the company’s fundamentals. Argus coverage reference
• Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-squeeze pressure. The figure may reflect a reporting or data issue and should be interpreted cautiously.
• Negative Sentiment: CEO Ugur Sahin sold 36,209 shares for approximately $3.45 million on October 9 and another 27,000 shares for about $2.49 million on October 8. The transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their significance as discretionary signals, but the sales substantially reduced his direct ownership. BioNTech CEO SEC filing
• Negative Sentiment: The latest quarterly results showed continuing commercial pressure: revenue fell 59.5% year over year to $122.31 million, below the $180.18 million consensus estimate, while the company reported a loss of $2.53 per share. Analysts expect a full-year loss, underscoring the need for BioNTech’s pipeline to offset declining COVID-19 vaccine revenue.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of research reports. Canaccord Genuity Group cut their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Morgan Stanley decreased their price target on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, UBS Group reiterated a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $125.69.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BNTX. Farther Finance Advisors LLC boosted its holdings in shares of BioNTech by 31.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after buying an additional 118 shares during the period. AlphaCentric Advisors LLC grew its stake in BioNTech by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock valued at $499,000 after buying an additional 305 shares during the last quarter. USS Investment Management Ltd raised its holdings in BioNTech by 1.2% in the 1st quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock valued at $2,854,000 after acquiring an additional 382 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in BioNTech during the second quarter worth approximately $39,000. Finally, Marks Group Wealth Management Inc lifted its position in BioNTech by 16.0% during the first quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock worth $307,000 after acquiring an additional 476 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.